Aysel Seferaliyeva

Dr. Aysel Seferaliyeva

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2026 in Cerrahpasa Medical Journal
Verified
Journal Article
Open access
PDF file
SÇSimay Çokgezer
Simay Çokgezer
MŞMuhammet şenkal
Muhammet şenkal
ASAysel Seferaliyeva
Aysel Seferaliyeva
HBHamza Ugur Bozbey
Hamza Ugur Bozbey
DTDidem Taştekin
Didem Taştekin
Objective: This study primarily aimed to identify baseline clinical and laboratory predictors of hematologic toxicity during first-line platinum-based chemotherapy in BRCA-mutated ovarian cancer patients. Secondary objectives included describing toxicity patterns and evaluating the association between hematologic toxicity and survival outcomes. Methods: This retrospective study included 64 patients with BRCA-mutated ovarian cancer who received platinum-taxane-based chemotherapy and were followed up at the İstanbul University Institute of Oncology between January 2009 and September 2024. Hematological toxicity was assessed using complete blood count before each chemotherapy cycle. Clinical data, factors associated with toxicity, and survival outcomes were compared between groups. Results: Hematologic toxicity occurred in 29.7% of the patients. The baseline leukocyte, neutrophil, and platelet counts were significantly lower in patients with toxicity. Additionally, patients with toxicities had more comorbidities at the baseline. Although the rate of dose modification was higher in the hematologic toxicity group, there were no significant differences between the groups in terms of treatment response or survival outcomes. Conclusion: Although hematologic toxicity was associated with more frequent dose modifications, no statistically significant differences in survival outcomes were observed between the groups. Baseline hematologic values and comorbidities should be considered in individualized planning of chemotherapy. Large-scale prospective studies are warranted to enhance the understanding of this topic. Cite this article as: Çokgezer S, Senkal M, Safaraliyeva A, Bozbey HU, Taştekin D. Hematologic toxicity during first-line platinum-based chemotherapy in BRCA-mutated ovarian cancer: predictors and survival impact. Cerrahpaşa Med J 2026; 50, 0033, doi: 10.5152/cjm.2026.26033.

16 January 2026 in Medicina
Verified
Journal Article
Open access
PDF file
SÇSimay Çokgezer
Simay Çokgezer
NANaziye Ak
Naziye Ak
MŞMuhammet şenkal
Muhammet şenkal
ASAysel Seferaliyeva
Aysel Seferaliyeva
DTDidem Tastekin
Didem Tastekin
PSPınar Mualla Saip
Pınar Mualla Saip
Background and Objectives: This study aimed to comparatively evaluate the association of commonly used comorbidity scores with survival, mortality, and recurrence in ovarian cancer patients aged 50 years and above. Materials and Methods: In this single-center, retrospective study, 130 female patients diagnosed between 2017 and 2024 who had received systemic therapy and had complete medical records were included. Comorbidity scores—including the Charlson Comorbidity Index (CCI), Cumulative Illness Rating Scale-Geriatric (CIRS-G), Adult Comorbidity Evaluation-27 (ACE-27), Elixhauser Comorbidity Index, Index of Coexistent Disease (ICED), and Functional Comorbidity Index (FCI)—were calculated for each patient. Survival analyses were conducted using the Kaplan–Meier method and Cox regression modeling. The prognostic accuracy of comorbidity scores was assessed via receiver operating characteristic (ROC) curve analysis. Results: Patients with higher CCI scores had significantly shorter survival, and CCI was identified as an independent prognostic factor in multivariate analysis. While other comorbidity scores were associated with overall survival in univariate analyses, they lost statistical significance in multivariate models. Patients with a higher comorbidity burden experienced more frequent disease recurrence and shorter time to recurrence. Conclusions: Comorbidity burden is a key clinical determinant of survival and disease trajectory in older patients with ovarian cancer. The CCI demonstrated the highest prognostic accuracy in this population and may serve as a valuable tool in individualized treatment planning. Integration of comorbidity-based assessments into standard decision-making processes is recommended in geriatric oncology practice.

25 November 2025 in Journal of Obstetrics and Gynaecology Research
Verified
Journal Article
Closed access
SÇSimay Çokgezer
Simay Çokgezer
MŞMuhammet şenkal
Muhammet şenkal
ASAysel Seferaliyeva
Aysel Seferaliyeva
HKHelin Kose
Helin Kose
IYInci Kizildag Yirgin
Inci Kizildag Yirgin
NANaziye Ak
Naziye Ak

28 March 2026 in Medicina
Verified
Journal Article
Open access
PDF file
SÇSimay Çokgezer
Simay Çokgezer
ASAysel Seferaliyeva
Aysel Seferaliyeva
STSevde Topuz
Sevde Topuz
MŞMuhammet şenkal
Muhammet şenkal
NANaziye Ak
Naziye Ak
PSPınar Mualla Saip
Pınar Mualla Saip
Background and Objectives: Invasive lobular carcinoma (ILC) is a breast cancer subtype with a controversial surgical management due to its diffuse infiltrative growth pattern and increased tendency for multicentricity. This study aimed to compare the effects of breast-conserving surgery (BCS) and mastectomy on long-term overall survival (OS) and progression-free survival (PFS) in patients diagnosed with ILC. Materials and Methods: In this single-center, retrospective, observational study, 255 patients with histopathologically confirmed ILC between 2017 and 2025 were included. Patients who underwent surgical treatment were divided into two groups according to the surgical approach: BCS (n = 94) and mastectomy (n = 141). Survival analyses were performed using the Kaplan–Meier method, and comparisons between groups were assessed with the log-rank test. Factors affecting survival were evaluated using Cox regression analysis. Results: The median age of the patients was 53 years (range, 28–85), and the median follow-up duration was 31.8 months. Of the cases, 76.9% were classic-type ILC and 70.9% had stage I–II disease. The rate of negative surgical margins was 87.6%. No statistically significant differences were observed between the BCS and mastectomy groups in terms of estimated median PFS (87.4 months vs. 86.7 months; p > 0.05) or estimated median OS (87.7 months vs. 115.7 months; p > 0.05). Multivariable analyses demonstrated that the type of surgery was not an independent prognostic factor for survival. Conclusions: This study shows that, with appropriate patient selection and adequate surgical margin control, BCS provides oncologic survival outcomes comparable to mastectomy in ILC. The choice of surgical approach should be individualized based on tumor biology, stage, and multidisciplinary evaluation rather than histological subtype alone.

30 June 2026 in Cerrahpasa Medical Journal
Verified
Journal Article
Open access
SÇSimay Çokgezer
Simay Çokgezer
MŞMuhammet şenkal
Muhammet şenkal
ASAysel Seferaliyeva
Aysel Seferaliyeva
STSevde Topuz
Sevde Topuz
PSPınar Mualla Saip
Pınar Mualla Saip
NANaziye Ak
Naziye Ak
Objective: This study aimed to compare disease-free survival (DFS) and overall survival (OS) between patients with hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative invasive lobular carcinoma (ILC) who received adjuvant chemotherapy plus endocrine therapy and those who received adjuvant endocrine therapy alone in a real-world setting. Methods: In this single-center retrospective cohort study, patients diagnosed with stage I-III HR-positive, HER2-negative ILC who underwent curative surgery between January 2017 and June 2025 were included. Patients with metastatic disease, prior neoadjuvant therapy, or incomplete follow-up were excluded. Patients were categorized according to receipt of adjuvant chemotherapy. All patients received standard adjuvant endocrine therapy. The primary endpoints were DFS and OS. Results: A total of 154 patients were included, with a median follow-up of 29.8 months. Patients who received adjuvant chemotherapy had higher-risk clinicopathological features, including more advanced tumor stage and nodal involvement. During follow-up, 6 recurrences (3.9%) were observed. Median DFS was 84.5 months in the endocrine therapy alone group and 95.5 months in the chemotherapy plus endocrine therapy group (log-rank P = .962). Median OS was not reached; the estimated mean OS was 96.4 months. Median OS was 85.6 months in the non-chemotherapy group and 95.8 months in the chemotherapy group (log-rank P = .785). In multivariable analysis, chemotherapy was not an independent predictor of DFS or OS. Conclusion: In this real-world cohort of HR-positive, HER2-negative ILC, no statistically significant difference in DFS or OS was observed between treatment groups. These findings should be interpreted with caution given the limited number of events and baseline risk imbalance. The potential survival benefit of chemotherapy in this subtype may be limited and should be considered in individualized treatment decisions. Cite this article as: Çokgezer S, Şenkal M, Safaraliyeva A, Topuz S, Saip PM, Ak N. Real-world survival outcomes of adjuvant chemotherapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative invasive lobular carcinoma. Cerrahpaşa Med J 2026, 50, 0038, doi: 10.5152/cjm.2026.26038.